Although not in cancer, kaempferol was found to alleviate fibrotic airway remodeling via bronchial EMT by modulating protease-activated receptor-1 (PAR1) activation, which was entailed by TGF-β, suggesting that it may be a potential therapeutic agent targeting asthmatic airway constriction [127]. This evidence concerns the gene F2R and cancer.